eJHaem (Nov 2023)
Complete remission of aggressive Epstein–Barr virus‐positive diffuse large B‐cell lymphoma following withdrawal of tacrolimus and low‐dose anticancer drugs
Abstract
Abstract A 66‐year‐old woman who had received tacrolimus for more than 11 years was admitted with high fever, generalized lymphadenopathy, and persistent gastrointestinal bleeding. Histopathological evaluation of the lymph nodes and colonic mucosa confirmed the diagnosis of Epstein–Barr virus‐positive diffuse large B‐cell lymphoma. After discontinuation of tacrolimus, the lymphoma did not improve, and low‐dose chemotherapy was introduced, which resulted in a recovery of lymphocyte counts and induction of complete remission. Low‐dose anticancer treatments that suppress tumor growth while awaiting normal lymphocyte recovery for several weeks may be a useful therapeutic option even for aggressive lymphomas that develop during immunosuppressant therapy.
Keywords